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Abstract
Objectives Previous attempts at meta-analysis and systematic
review have not provided clear recommendations for the clin-
ical application of thermal ablation in metastatic colorectal
cancer. Many authors believe that the probability of gathering
randomised controlled trial (RCT) data is low. Our aim is to
provide a consensus document making recommendations on
the appropriate application of thermal ablation in patients with
colorectal liver metastases.
Methods This consensus paper was discussed by an expert
panel at The Interventional Oncology Sans Frontières 2013.
A literature review was presented. Tumour characteristics, ab-
lation technique and different clinical applications were con-
sidered and the level of consensus was documented.
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Results Specific recommendations are made with regard to
metastasis size, number, and location and ablation technique.
Mean 31 % 5-year survival post-ablation in selected patients
has resulted in acceptance of this therapy for those with tech-
nically inoperable but limited liver disease and those with
limited liver reserve or co-morbidities that render them
inoperable.
Conclusions In the absence of RCT data, it is our aim that this
consensus document will facilitate judicious selection of the
patients most likely to benefit from thermal ablation and pro-
vide a unified interventional oncological perspective for the
use of this technology.
Key Points
• Best results require due consideration of tumour size, num-
ber, volume and location.
• Ablation technology, imaging guidance and intra-
procedural imaging assessment must be optimised.
• Accepted applications include inoperable disease due to
tumour distribution or inadequate liver reserve.
• Other current indications include concurrent co-morbidity,
patient choice and the test-of-time approach.
• Future applications may include resectable disease, e.g. for
small solitary tumours.
Keywords Colorectal neoplasms . Liver neoplasms .
Ablation techniques . Consensus . Clinical protocols
Introduction
Colorectal cancer is the second most common cause of cancer
death in developed countries and the third most common ma-
lignancy worldwide [1]. Fifty percent of patients develop liver
metastases yet only a minority (10–15%) can undergo hepatic
resection. Five-year survival following liver resection ranges
between 31 % and 58 % in carefully selected patients [2, 3].
The remainder are usually offered chemotherapy and/or local
tumour ablation. Median survival following systemic treat-
ment is now of the order of 20–22 months in patients who
receive biological agents and multiple sequential chemother-
apy regimes, 5-year survival remains close to 0 %. Five-year
survival following ablation varies between 17 % and 51 %
(Table 1). Our aim is to present a consensus paper with rec-
ommendations on how radiofrequency and other types of ther-
mal ablation should be built into the overall management plan
of patients with colorectal liver metastases. The need for ro-
bust long-term follow-up data meant that this paper concen-
trated on radiofrequency (RF) ablation, the only thermal abla-
tion source at present with substantial follow-up literature. RF
ablation was first performed in the early 1990s and in the first
few years there were a number of significant changes in tech-
nology which resulted in improved ablation efficacy [8, 9]. By
the late 1990s and early 2000s ablation was becoming
accepted in the interventional radiology community but was
still viewed with some scepticism by the oncology and surgi-
cal communities. The first few surgical papers from the early
2000s reflect this, but more recently there has been genuine
enthusiasm for a technique that can deliver effective focal
therapy to many more patients than could be treated with
resection alone [10–12]. The effectiveness and the limitations
of RF ablation are now well understood. The question of
where ablation fits in the overall management of patients with
metastatic colorectal cancer is still being debated. In the last
few years there have been numerous reviews of the ablation
literature [13–26]. All of these have concluded that there is
insufficient data, in particular randomised controlled trial
(RCT) data, and as a result have had difficulty providing rec-
ommendations on the role of ablation. Attempts at RCT have
not been successful due to difficulties in randomisation, cross-
over between treatment arms, changes in chemotherapy re-
gimes and expense. However, many ablation practitioners
and early pioneers feel that the field has sufficiently matured
for initial recommendations to be made. The following con-
sensus document was discussed at a meeting of ablation ex-
perts which included more than 25 interventional oncologists,
from around the world, all of whom had substantial personal
experience in liver ablation.
Materials and methods
An initial draft was prepared for discussion and circu-
lated prior to The International Oncology Sans
Frontières Congress 2013. This document was then
discussed and specific recommendations were made.
Each recommendation, such as tumour size, was put to
a vote, by an open show of hands. The document was
then modified and disseminated electronically for com-
ment. Feedback on subsequent versions was received
from all authors. Each recommendation is accompanied
with a description of the level of consensus achieved.
Where there was consensus among all or nearly all
(>95 %) members, the consensus level is described as
strong. Where the majority (>80 % of experts) but not
all agreed, the level of consensus is described as mod-
erate. Only recommendations where >80 % consensus
was achieved are included.
These guidelines are based on experience with radiofre-
quency ablation as the need for long-term follow-up data
meant that there was insufficient data for some of the newer
technologies, such as microwave (MW) and irreversible elec-
troporation (IRE). Cryoablation and laser ablation are not
widely implemented in colorectal liver metastases and again
the data is limited. When more data, for example from high
power MW, becomes available a revision of the current rec-
ommendations will be considered.
Eur Radiol (2015) 25:3438–3454 3439
T
ab
le
1
Su
rv
iv
al
fo
llo
w
in
g
ab
la
tio
n
of
co
lo
re
ct
al
liv
er
m
et
as
ta
se
s.
Pa
pe
rs
w
er
e
in
cl
ud
ed
if
:O
nl
y
pa
tie
nt
s
w
ith
co
lo
re
ct
al
liv
er
m
et
as
ta
se
s
w
er
e
in
cl
ud
ed
.A
m
in
im
um
of
50
pa
tie
nt
s
w
er
e
tr
ea
te
d
w
ith
ab
la
tio
n.
M
or
e
th
an
3
ye
ar
su
rv
iv
al
w
as
pr
ov
id
ed
.W
he
re
m
ul
tip
le
pa
pe
rs
w
er
e
pu
bl
is
he
d
by
th
e
sa
m
e
gr
ou
p
ov
er
se
ve
ra
ly
ea
rs
,t
he
m
os
tc
om
pl
et
e/
re
ce
nt
pa
pe
r
w
as
us
ed
A
ut
ho
r
N
o
of
pt
s
P
at
ie
nt
po
pu
la
tio
n:
-n
o
of
pa
tie
nt
s
w
ith
re
se
ct
ab
le
di
se
as
e
(R
D
)
vs
.u
nr
es
ec
ta
bl
e
di
se
as
e
(U
D
)
A
pp
ro
ac
h
to
ab
la
tio
n:
M
ea
n/
M
ed
ia
n
no
of
tu
m
ou
rs
M
ea
n/
M
ed
ia
n
di
am
et
er
(c
m
)
E
xt
ra
-h
ep
at
ic
di
se
as
e
(E
H
D
)
%
3
yr
su
rv
iv
al
4
yr
su
rv
iv
al
5
yr
su
rv
iv
al
7,
8
&
10
yr
su
rv
iv
al
C
om
m
en
t
A
bd
al
la
et
al
.
(2
00
4)
[4
]
41
8
M
ix
ed
R
D
an
d
U
D
R
F
in
57
U
D
O
pe
n
R
F
1
(1
-8
)
R
F
2.
5
0
R
F
37
%
R
F
22
%
U
nf
av
ou
ra
bl
e
co
m
pa
ri
so
n
of
ab
la
tio
n
to
re
se
ct
io
n,
si
m
ila
r
re
su
lts
in
ab
la
tio
n
+
re
se
ct
io
n
vs
.a
bl
at
io
n
al
on
e.
Fa
vo
ur
ab
le
co
m
pa
ri
so
n
to
ch
em
ot
he
ra
py
in
liv
er
on
ly
di
se
as
e
pa
tie
nt
s
bu
t
di
ff
er
en
tp
at
ie
nt
po
pu
la
tio
ns
.
A
gc
ao
gl
u
et
al
.
(2
01
3)
[5
]
39
5
M
ix
ed
R
D
an
d
U
D
R
F
in
29
5
U
D
L
ap
ar
os
co
pi
c
R
F
3
(1
-1
1)
R
F
3.
4
R
F
22
R
F
17
%
U
se
d
la
pa
ro
sc
op
ic
R
F
ab
la
tio
n
to
ex
te
nd
th
er
ap
eu
tic
en
ve
lo
pe
in
pa
tie
nt
s
w
ith
U
D
B
al
e
et
al
.
(2
01
2)
[6
]
63
37
U
D
26
R
D
Pe
rc
ut
an
eo
us
2
(1
-1
4)
2
(0
.5
-1
3)
0
44
%
27
%
Si
gn
if
ic
an
tly
di
ff
er
en
to
ut
co
m
e
be
tw
ee
n
R
D
an
d
U
D
G
ill
am
s
an
d
L
ee
s
(2
00
9)
[7
]
12
3
U
D
Pe
rc
ut
an
eo
us
2.
1
(1
-5
)
2.
9
(0
.9
-5
)
0
49
%
24
%
A
su
bp
op
ul
at
io
n
of
69
pa
tie
nt
s
w
ith
<
3
tu
m
ou
rs
,<
3.
5
cm
di
am
et
er
(a
ct
ua
ln
um
be
r
1.
7,
m
ea
n
si
ze
2.
2
cm
)
ha
d
5
yr
su
rv
iv
al
of
33
%
H
am
ad
a
et
al
.
(2
01
2)
[2
9]
84
U
D
Pe
rc
ut
an
eo
us
1.
7
2.
3
(0
.5
-9
)
27
45
%
21
%
O
n
m
ul
tiv
ar
ia
te
an
al
ys
is
tu
m
ou
r
si
ze
>
3
cm
,m
ul
tip
le
tu
m
ou
rs
,
pr
io
r
ch
em
ot
he
ra
py
an
d
un
co
nt
ro
lle
d
E
H
D
w
er
e
si
gn
if
ic
an
t
H
am
m
ill
et
al
.
(2
01
1)
[3
0]
10
1
M
ix
ed
bu
ta
ll
R
x
w
ith
R
F
R
D
64
U
D
37
L
ap
ar
os
co
pi
c
1.
6
R
D
3.
5
U
D
3
R
D
4
U
D
0
49
%
R
D
18
%
U
D
R
F
ca
n
pr
ov
id
e
si
m
ila
r
re
su
lts
to
re
se
ct
io
n
in
se
le
ct
ed
pa
tie
nt
s
Ja
ko
bs
et
al
.
(2
00
6)
[3
1]
68
U
D
Pe
rc
ut
an
eo
us
2.
7
2.
3
(0
.5
–
5)
0
68
%
K
im
et
al
.
(2
01
1)
[3
2]
50
5
M
ix
ed
R
D
an
d
U
D
R
F
17
7
in
U
D
du
e
to
co
m
or
bi
di
ty
,
>
4
sc
at
te
re
d
tu
m
ou
rs
,d
if
fi
cu
lt
si
te
fo
r
re
se
ct
io
n
O
pe
n
an
d
Pe
rc
ut
an
eo
us
R
F
1.
6
R
F
2.
1
(0
.5
-6
.2
)
0
Si
ng
le
tu
m
ou
rs
<
3
cm
R
F
51
%
Sa
m
e
%
ov
er
al
l(
51
,5
1)
an
d
di
se
as
e
fr
ee
su
rv
iv
al
(3
4,
32
)
fo
r
pa
tie
nt
s
w
ith
si
ng
le
tu
m
ou
rs
<
3
cm
tr
ea
te
d
w
ith
R
F
ab
la
tio
n/
re
se
ct
io
n.
M
ac
hi
et
al
.
(2
00
6)
[3
3]
10
0
U
D
Pe
rc
ut
an
eo
us
61
L
ap
ar
os
co
pi
c
23
O
pe
n
62
3.
5
al
l,
Pe
rc
ut
an
eo
us
2.
3,
L
ap
ar
os
co
pi
c
2.
7,
op
en
4.
9
3.
0
al
l,
Pe
rc
ut
an
eo
us
3.
5,
L
ap
ar
os
co
pi
c
2.
3
O
pe
n
2.
8
20
al
lP
er
cu
ta
ne
ou
s
30
,L
ap
ar
os
co
pi
c
0,
O
pe
n
18
42
%
31
%
M
ed
ia
n
su
rv
iv
al
of
30
m
on
th
s
in
pa
tie
nt
s
w
ith
no
E
H
D
vs
.
20
m
on
th
s
in
th
os
e
w
ith
E
H
D
Ty
pe
of
ap
pr
oa
ch
ce
as
ed
to
be
si
gn
if
ic
an
to
n
M
V
an
al
ys
is
3440 Eur Radiol (2015) 25:3438–3454
T
ab
le
1
(c
on
tin
ue
d)
A
ut
ho
r
N
o
of
pt
s
Pa
tie
nt
po
pu
la
tio
n:
-n
o
of
pa
tie
nt
s
w
ith
re
se
ct
ab
le
di
se
as
e
(R
D
)
vs
.u
nr
es
ec
ta
bl
e
di
se
as
e
(U
D
)
A
pp
ro
ac
h
to
ab
la
tio
n:
M
ea
n/
M
ed
ia
n
no
of
tu
m
ou
rs
M
ea
n/
M
ed
ia
n
di
am
et
er
(c
m
)
E
xt
ra
-h
ep
at
ic
di
se
as
e
(E
H
D
)
%
3
yr
su
rv
iv
al
4
yr
su
rv
iv
al
5
yr
su
rv
iv
al
7,
8
&
10
yr
su
rv
iv
al
C
om
m
en
t
M
ed
ia
n
su
rv
iv
al
of
48
m
on
th
s
in
th
os
e
w
ith
R
F
ab
la
tio
n
pr
io
r
to
ch
em
ot
he
ra
py
vs
.2
2
m
on
th
s
in
th
os
e
w
ith
R
F
ab
la
tio
n
af
te
r
ch
em
ot
he
ra
py
R
eu
te
r
et
al
.
(2
00
9)
[3
4]
19
2
M
ix
ed
R
D
an
d
U
D
R
F
in
66
U
D
O
pe
n
R
F
2.
8
R
F
3.
2
R
F
15
R
F
21
%
Po
or
er
PF
S
fo
r
R
F
ab
la
tio
n
as
co
m
pa
re
d
w
ith
re
se
ct
io
n
bu
t
th
e
sa
m
e
ov
er
al
ls
ur
vi
va
l.
5
yr
su
rv
iv
al
23
%
af
te
r
re
se
ct
io
n
vs
.2
1
%
fo
r
R
F.
N
ot
e
re
se
ct
io
n
w
as
us
ed
in
la
rg
er
tu
m
ou
rs
,m
ea
n
5.
3
cm
vs
.
3.
2
cm
fo
r
R
F
ab
la
tio
n
So
fo
cl
eo
us
et
al
.
(2
01
1)
[3
5]
56
U
D
(P
os
tr
es
ec
tio
n)
Pe
rc
ut
an
eo
us
1.
3
(1
-4
)
1.
9
(0
.5
–
5.
7)
30
41
%
R
F
ab
la
tio
n
as
sa
lv
ag
e
in
po
or
ri
sk
pa
tie
nt
s
So
lb
ia
ti
et
al
.
(2
01
2)
[3
6]
99
U
D
(6
0)
R
D
(3
9)
Pe
rc
ut
an
eo
us
2
2.
2
(0
.8
-4
)
7
69
%
48
%
7
yr
25
%
10
yr
18
%
So
re
ns
en
et
al
.
(2
00
7)
[3
7]
10
2
U
D
(1
00
)
R
D
(2
,p
at
ie
nt
ch
oi
ce
)
Pe
rc
ut
an
eo
us
15
3
O
pe
n
25
3.
3
(1
-1
7)
2.
2
(0
.5
-6
.5
)
0
46
%
26
%
V
an
Ti
lb
or
g
et
al
.
(2
01
1)
[3
8]
10
0
U
D
O
pe
n
22
1
Pe
rc
ut
an
eo
us
16
2.
4
2.
4
(0
.2
-8
.3
)
L
im
ite
d
an
d
tr
ea
ta
bl
e
by
re
se
ct
io
n,
R
T
or
R
F
77
%
36
%
8
yr
24
%
Si
ze
an
d
no
.w
er
e
si
gn
if
ic
an
t
Pe
rc
ut
an
eo
us
ap
pr
oa
ch
ch
os
en
fo
r
re
cu
rr
en
ce
,s
m
al
l
su
pe
rf
ic
ia
lt
um
ou
rs
,c
o-
m
or
bi
d
an
d
el
de
rl
y
pa
tie
nt
s
V
el
tr
ie
ta
l.
(2
00
8)
[3
9]
12
2
U
D
Pe
rc
ut
an
eo
us
10
8
O
pe
n
14
1.
6
2.
9
(0
.5
-8
)
21
38
%
22
%
T
um
ou
r
si
ze
im
pa
ct
ed
su
rv
iv
al
<
3
cm
36
m
on
th
s
vs
.
>
3
cm
23
m
on
th
s
su
rv
iv
al
Eur Radiol (2015) 25:3438–3454 3441
Literature review
A PubMed search of the literature from 1998 to March 2013
using the search terms: colorectal and ablation; treatment and
colorectal liver metastases; radiofrequency ablation and liver
metastases; ablation and liver metastases, produced in excess
of 5000 results. These were further refined by only including
papers specifically related to colorectal liver metastases and
radiofrequency ablation technology with a defined minimum
length of follow-up and minimum numbers of patients. The
rationale for this was that all new techniques and procedures
have an intrinsic learning curve. This was well studied at the
time of introduction of laparoscopic cholecystectomy and
again for laparoscopic-assisted colectomy and has also been
shown to be true of ablation [27, 28]. Mulier estimated that
treatment of at least 100 liver tumours was required for the
mastery of RF ablation [28]. Accordingly, in most series the
mean number of tumours treated per patient is two, and there-
fore series with a minimum of 50 patients (i.e. approximately
100 tumours in total) with colorectal liver metastases treated
with RF and 3-year follow-up were included in the survival
analysis (Table 1) [4–7, 29–39]. Furthermore, papers that did
not separate the results of ablation with or without resection
were not included, as this confounding variable could poten-
tially obscure results. To avoid duplication of reporting, for
those centres with multiple publications over many years, the
most recent or most comprehensive report was selected. Ab-
stracts were not included as this format does not provide suf-
ficient detail for the study to be analysed.
All authors defined patients as having resectable or
unresectable disease and RF ablation was almost without
exception applied to patients with unresectable disease; details
of the population have been specified. Of the 15 papers, four
used both open and percutaneous approaches, two open only,
two laparoscopic only, six percutaneous only and one used all
three approaches. Four of the papers included resection, abla-
tion and combined resection and ablation data. For our surviv-
al analysis we have shown the results from the ablation
subgroup.
Survival analysis
The total population of patients who underwent RF ablation
from the 15 papers was 1613. Mean tumour number per pa-
tient was 2.2 (1–3.5) and mean tumour size 2.6 cm (1.7–4).
Eight papers included patients with extra-hepatic disease but
one specified that all sites of extrahepatic disease were poten-
tially treatable by resection, radiotherapy or ablation. The
mean 3-year survival from the date of first thermal ablation
was 50 % (37–77 %) and the mean 5-year survival was 31 %
(17–51%). Nearly all studies used RF ablation in patients with
unresectable disease, but when ablation was applied to pa-
tients with potentially resectable disease the 5-year survival
increased to 50 %. The mean 5-year survival for the percuta-
neous, laparoscopic and open approaches were 30 %, 28 %
and 21 %, respectively.
Table 2 shows a summary of morbidity, mortality and hos-
pital stay for the percutaneous, laparoscopic and open ap-
proaches with comparison to resection and combined resec-
tion and ablation. Table 3 shows the local recurrence rates
according to procedural approach and size of tumour ablated.
Table 2 Mortality, morbidity and
hospital stay Category Mortality, % Major complications,
%
Hospital stay, mean days
(range)
Open resection 1–5 [4, 5] 25–30 [37]
21 [32]
13 (5–55) [40]
13.4 [32]
9.8 [34]
Combined open RF
ablation+resection
4.5 [40] 37 [32]
32 [40]
15 [32]
Open RF ablation 2.3 [41]
1.1 [42]
0.0 [34]
32 [41]
10 [34]
9.6 [42]
6.6 [34]
4.2 [32]
Laparoscopic
RF ablation
0.3 [5]
0.0 [30]
4.4 [5]
3.1 [30]
3.3 [30]
Percutaneous
RF ablation
0.0 [7, 29, 31, 35–37] 4.7 [7]
4.0 [35]
2.2 [29]
1.3 [36]
1.1 [39]
0.0 [31]
2 (1–9) [40]
1.3 [43]
1.0 [7]
RF radiofrequency
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Recommendations – tumour and technique specific
considerations (Table 4)
Tumour size (maximum longitudinal diameter in the axial
plane (cm))
Thermal ablation is particularly effective in treating small-
to medium-sized tumours. Many series report attempts at
treating tumours larger than 5 cm in diameter, even up to
11 or 12 cm, but the incomplete ablation rate and local
recurrence rate for these large tumours is very high and so
these patients are better served by other treatment modal-
ities. Analysis of local recurrence rates and survival
shows an advantage for small tumours. These are detailed
in Table 3 where consistently lower local tumour progres-
sion is reported with reducing tumour size. The most
common cut-off point is 3 cm [29, 30, 36, 39]. However,
tumours up to 5 cm can be completely ablated and per-
manently eradicated depending on their anatomical posi-
tion and the treatment protocol used. For example,
Hammil et al. [30] reported a 3 % local recurrence rate
for <3-cm tumours and a 4 % recurrence rate for 3- to 5-cm
tumours. Recurrence rates for >5 cm tumours ranges from 27–
45 % and so thermal ablation with curative intent is not gen-
erally recommended for metastases >5 cm [30, 42].
The consensus was that smaller, <3 cm, tumours are more
straightforward to treat than larger tumours, but that well lo-
cated tumours <5 cm can be effectively treated depending on
their anatomical position and the treatment protocol used.
Well located tumours are defined as those with easy access,
located such that clear margins can be achieved.
Consensus level: strong.
Tumour number
As ablation is a focal, minimally invasive technique, there is a
limit to the number of tumours that can be successfully treated.
Most centres will accept patients with five tumours or less.
Some centres treat up to nine tumours, if the maximum diam-
eter is <4 cm, and usually at two treatment sessions [48, 49].
As in the resection literature, the best results are achieved in
solitary tumours, Gillams et al. [32] reported 3-year survival in
excess of 80 % and Kim et al. [50] reported 5-year survival of
51 % in solitary tumours. Additional tumours that develop
during follow-up, including new tumours in the post-
resection liver remnant or local recurrence, should be consid-
ered for ablation based upon anatomical and size criteria.
The consensus was that patients with five or fewer tumours
should routinely be considered for ablation and that patients with
nine or fewer tumours should be considered in selected cases.
Consensus level: strong.
Overall liver tumour volume
In addition to the size and number of individual tumours, the
overall liver tumour volume is also important. For example, in
the EORTC 4004 (CLOCC) trial patients with nine or fewer
tumours were treated, but the maximum individual tumour
diameter allowed was 4 cm [49]. A crude overall liver tumour
volume can be calculated from the product of the mean max-
imum tumour size and mean number. Analysis of the 5-year
survival in four papers where patients without extra-hepatic
disease were treated shows a direct correlation between crude
liver tumour volume and survival with the best results in those
with small volume disease (R2 0.7) (Fig. 1) [7, 30, 32, 38]. We
would therefore recommend that in addition to size and
Table 4 Summary of recommendations. Tumour and technical considerations
Parameter Preferred Caveat
Tumour size <3 cm Well located tumours <5 cm may be suitable for ablation
Tumour number 1–3 optimal, <5 preferable 6–9 maximum
Tumour location next to
major bile ducts
Avoid Consider high flow biliary cooling via nasobiliary tubes
or other non-thermal interventional oncology techniques
Tumours located in contact w
ith blood vessels
Suitable for ablation with careful follow-up
and repeat treatment if necessary
Consider more intensive RF ablation to compensate for
blood flow cooling, could consider IRE or MW
Tumours located within 1 cm of
vulnerable structures, e.g. colon
Require displacement from the ablation
zone using adjunctive measures, e.g.
percutaneous hydro- or gas-dissection
Laparoscopic approach if adequate separation cannot
be achieved percutaneously
Extra-hepatic disease (EHD) Suitable for liver ablation as long as all sites
of EHD disease are radically treated
Palliative liver ablation in patients with more extensive
EHD is not recommended
Local recurrence should
be minimised by:
1. Achieving >1 cm ablation margins in 3D
2. Maximising operator experience
3. GA should be available as required
4. Optimal definition of the tumour
5. Optimal intra-procedural assessment
of the ablation zone
Conscious sedation procedures are an acceptable alternative
in unfit patients
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number of tumours, the total liver tumour volume is taken into
consideration.
Consensus level: strong
Relationship to central bile ducts
Ablation to within 1 cm of the major bile ducts (common bile
duct, common hepatic, right and left hepatic ducts) runs the risk of
bile duct injury [51]. The secondary effects, cholangitis and liver
abscesses can be very significant, particularly if the patient re-
quires chemotherapy at some later date. Therefore thermal abla-
tion in this area is not recommended unless the bile ducts can be
effectively protected. There is limited data suggesting high-flow
bile duct cooling, for example via a nasobiliary tube, is effective in
protecting the bile ducts [52]. Alternative techniques such as IRE,
stereotactic body radiotherapy or transarterial therapies could be
considered [53]. The consensus is that central bile ducts must be
effectively protected or alternative technologies sought.
Consensus level: strong
Relationship to blood vessels
Ablation of tumours next to blood vessels is more difficult due
to the cooling effect of blood flow. Ablation can be applied to
tumours in contact with larger vessels (>3 mm in diameter)
accepting an increased risk for tumour recurrence and the need
for more than one treatment. This well known phenomenon
has not been quantified in detail, but the risk of recurrence
varies with the size of the vessel, the ablation technology
and the length of vessel contact with the tumour. Strategies
to ablate more vigorously next to blood vessels have been
successfully adopted by many centres but are not part of stan-
dard commercial protocols. These strategies include increased
power or duration of ablation next to the vessel or preferential
placement of applicators towards the vessel side of the tumour.
The patient and referring clinician should be advised as to the
possible need for repeat treatment and the necessity of appro-
priate follow-up to detect and treat early tumour re-growth and
so control the liver tumour load. Alternative technologies, for
example microwave and IRE, may also have a role [54].
Consensus level: strong
Proximity to vulnerable structures
Ablation in close proximity to vulnerable structures, such as
the colon, requires measures to create an acceptable safety
margin or an operative approach [40]. Percutaneous hydro/
gas dissection is a simple and very effective technique and
should be part of the routine armamentarium of any ablation
practice [55–57].
Consensus level: strong
As size, number and location are all important features,
there is a strong consensus that these three factors should be
considered in concert when evaluating the appropriateness of
ablation in any given patient.
Patients with small volume, ablatable liver metastases
and extra-hepatic disease
Patients with extra-hepatic disease can be divided into
those with limited, treatable extra-hepatic disease, by re-
section, ablation or radical radiotherapy, and those with
more extensive disease for which the only treatment option
is chemotherapy. The first group can benefit from ablation
in the liver if the primary site and others sites of extra
hepatic disease are radically treated, for example ablation
of small volume lung metastases [58–60]. Liver ablation in
patients with more extensive extra-hepatic disease is of
uncertain value. There is a wide range of survival reported
for this group depending on volume of disease, sites in-
volved, chemotherapy regimen and response, but in one
paper the 5-year survival for 85 patients who had extra-
pulmonic, extra-hepatic disease but limited liver disease
treated with liver ablation was only 3 % [7]. The optimal
ablation patient, as for resection, has disease limited to the
liver.
Consensus level: strong
Maximising local tumour control
Many studies show higher local recurrence rates after ablation
than after resection (Table 3). The ease of repeated treatment,
particularly by the percutaneous approach, compensates to a
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degree for the higher local recurrence rate. This was confirmed
in a study by Otto et al. [61] where RF ablation was performed
as first-line treatment for smaller tumours, median 3 cm (range
1–5 cm), and resection was used for larger tumours, median
5 cm (range 1–14 cm). The estimated 5-year survival was
similar: 48 % for ablation and 51 % for resection. The local
recurrence rate was higher following ablation but there were
more options for repeat intervention (either surgery or abla-
tion) for new or recurrent disease, an important feature as most
stage IV cancer patients will have multiple metastatic events.
Similarly, Reuter et al. [34] showed different rates of disease-
free progression between the resection and ablation group but
overall survival was the same. Nevertheless, it is still of major
importance to get good local tumour control (i.e. <5 % local
tumour progression) and ideally percutaneous ablation would
provide both excellent local tumour control and the option for
repeated treatments for new metastases.
In addition to the factors already discussed such as tumour
size, what else should we do to maximise local tumour control?
a. Obtaining adequate ablative margins is essential
(strong consensus)
Colorectal liver metastases are less well perfused than the
surrounding liver so it is easier to ablate to the tumour
edge than to ablate the normally perfused liver around the
metastasis which is required in order to achieve an abla-
tive margin [62]. Applicators need to be positioned spe-
cifically to achieve a margin. A minimum 1-cm ablation
margin is required in all directions or to the edge of the
liver to maximise the likelihood of complete ablation.
Greater than 1-cm margins further reduces the likelihood
of local tumour progression [47].Margins are particularly
important where tumour definition is poor, for example in
downsized tumours following chemotherapy.
b. Excellent definition of the extent of the tumour is re-
quired (strong consensus)
Contrast-enhanced imaging is recommended. Several studies
show high local tumour recurrence rates where un-enhanced
ultrasound (US), un-enhanced computed tomography (CT)
or CT fluoroscopy have been used [29, 39, 46, 47].
c. Operator experience (strong consensus)
Experience with performing a minimum of 100 liver tu-
mour ablations has been correlated with decreased recur-
rence rates. Each ablation technology/device has a differ-
ent set of properties. Limited experience with multiple
different devices is particularly unhelpful as it further
dilutes the operator experience.
d. General anaesthesia (GA) (strong consensus)
The use of GA increases the rate of complete ablation
[28]. Consequently GA should be freely available to be
used at the discretion of the interventional oncologist. In
patients who are not fit enough for GA, a moderate con-
scious sedation procedure is a valid option [63].
e. Pre-procedural assessment scans should be less than
2 weeks old (strong consensus)
The mean volume doubling time of colorectal liver me-
tastases is 100 days therefore recent studies are needed
for patient selection. Detailed confirmatory imaging at
the time of treatment will facilitate complete ablation.
f. Monitoring ablation results at the time of treat-
ment using contrast-enhanced CT, MRI or US and
performing more ablation as needed, with further
applicator insertions, higher power or additional
treatment duration, at the same session will increase
the chances of complete ablation with adequate mar-
gins in all dimensions. We therefore strongly recom-
mend contrast-enhanced intra-procedural CT, MRI or
US [64] (strong consensus).
Current clinical Indications for thermal ablation
(Fig. 2, Table 5)
Patients with non-resectable disease due to number
and distribution of metastases should receive ablation±
chemotherapy instead of systemic chemotherapy alone
The last 15 years have seen a marked improvement in both
response rates and survival following systemic chemotherapy.
Median survival is now of the order of 20–22 months in pa-
tients who receive biological agents and multiple sequential
chemotherapy regimes [65]. Nevertheless, 5-year survival is
close to 0 % unless patients can undergo and benefit from
surgery. RF ablation has been successfully applied in patients
with non-resectable, small-volume liver disease, often in con-
junction with chemotherapy, and this has resulted in 3-year
survival rates of 37–77 % and 5-year survival rates of 17–
51 % (Table 1) [4–7, 29–39]. Abdalla compared ablation in
unresectable patients with chemotherapy in un-ablatable pa-
tients, all with liver-only disease, and showed a significant
improvement in survival in the ablation group median surviv-
al: 25 months versus 16.5 months (p=0.005) [4]. Even though
in this study RF ablation was applied to a different population
than those receiving chemotherapy alone, who may have had
more numerous or larger tumours, both groups had liver-only
disease at surgical staging, had potentially curable disease on
pre-operative staging, andwere sufficiently fit to undergomajor
surgery, thus many consider that this marked improvement in
survival in the RF ablation group is likely to reflect a benefit.
There has been one RCT (EORTC 4004, CLOCC
trial) which aimed to study the benefit of adding abla-
tion to systemic chemotherapy in patients with initially
inoperable metastases. Inevitably there was an element
of cross-over, so 5/59 (8.5 %) of those in the non-
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ablation arm were successfully downsized on chemo-
therapy, and subsequently underwent surgical resection
[49]. This study suffered from slow accrual, was initial-
ly a phase III study but was downgraded to a phase II
study, and closed early. As a result it was not sufficient-
ly powered to allow assessment of differences in overall
survival but did show significant differences in
progression-free survival (PFS) at 3 years: 27.6 % in
the ablation arm versus 10.6 % in the non-ablation
arm (p=0.025). The overall survival in the non-
ablation arm was much higher than expected and there
were also significant differences in salvage therapy be-
tween the two groups with the non-ablation arm receiv-
ing more systemic treatment. Differences in overall sur-
vival at 30 months were not significant, but the survival
curves continue to separate on follow-up; 47 % versus
36 % at 4 years and 40 % versus 30 % at 5 years.
The most common approach to patients presenting
with non-resectable disease is to use downsizing with
neoadjuvant chemotherapy followed by resection±portal
vein embolisation and/or staged resection. However, the
survival results of resection following portal vein embo-
lisation are only 25 % at 5 years [66]. Furthermore,
nearly 40 % of patients undergoing portal vein emboli-
sation never get to resection and many patients planned
for staged resection also fail to complete the course of
treatment [67, 68]. Some, but not all, of these patients
will have ablatable disease with comparable 5-year sur-
vival post-ablation but a higher chance of completing
radical treatment to all sites of disease. Therefore, abla-
tion should be considered in those with ablatable dis-
ease particularly if they fail to develop adequate liver
volumes post-portal vein embolisation.
There is now general agreement that RF ablation is a
useful adjunct to systemic treatment and it is widely
applied in non-resectable but limited liver-only disease.
For precise details on the appropriate tumour size, num-
ber and tumour location for ablation please see the sec-
tion on tumour specific parameters.
Consensus level: strong
Patients with non-resectable disease due to inadequate
liver reserve either because of prior resection or widely
scattered tumours
Ablation is an accepted treatment for patients with small
volume disease which cannot be resected due to limited
liver reserve including most patients who have had a
previous major liver resection [69]. Forty to 70 % of
patients will develop new metastases after even a suc-
cessful resection, with clear margins on pathological
analysis, and the majority cannot undergo repeat resec-
tion [12, 70, 71]. Ablation is indicated in those inoper-
able patients who have limited, liver-only disease with
or without chemotherapy.
The authors advise that additional factors to be considered
are:
– access, for example to a high left lobe liver remnant
which may require a transthoracic approach
– the possibility of post-resection portal hypertension with
low platelets and upper abdominal venous collaterals
which may affect the chosen electrode trajectory
– the relationship of any tumour to a single remaining he-
patic vein, portal vein branch or major bile duct that sub-
tends a significant percentage of the remnant liver and
could be damaged by ablation.
The risk of transient liver failure post-ablation in metastatic
disease with a normal volume and normal functioning back-
ground liver parenchyma is very low and has only been de-
scribed in two patients from a total cohort of 309 (0.6%); both
patients had undergone extended prior resection and at the
time of ablation had only one and two remaining liver seg-
ments, respectively [4].
Consensus level: strong
Limited, liver metastases with no 
or radically treatable extra-hepatic 
disease 
Must be fit with 
Sufficient hepatic reserve 
Clustered tumours are 
preferable
Tumour size not > 5 cm 
Widely distributed tumours 
Insufficient liver reserve 
Less fit patients 
Resection  Percutaneous 
ablation 
Adjuvant chemotherapy 
and surveillance 
No 
recurrence 
New 
disease 
Fig. 2 Management algorithm for patients presenting with colorectal
liver metastases
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The role and approach to ablation in a patient
with resectable disease but patient co-morbidity,
for example cardiac, renal or respiratory disease, prevents
a major procedure
Liver resection remains a major procedure which is not appli-
cable to less fit patients. Liver resection still carries a finite
mortality risk although mortality rates in experienced modern
surgical practices should be less than 3 % and certainly less
than 5 %. Major morbidity is still high at approximately 25–
30 %. Morbidity can be even higher, up to 40 %, in the over
70-year age group [72]. Percutaneous RF ablation ismuch less
invasive, mortality is rare and major complication rates below
2.5 % have been reported from several experienced centres
[29, 31, 36, 39]. All centres should aim for a major morbidity
of <5 % and for the treatment of small volume disease (fewer
than three tumours, <3 cm in diameter) <2 %. Both laparo-
scopic and open RF ablation carry a higher morbidity, require
general anaesthesia, entail a longer hospital stay and increased
cost, and should be reserved for specific indications. Open RF
ablation without resection still carries a small mortality
(<2.3 %) and the major complication rate varies between
9.6 % and 32 % (Table 2) [34, 41, 42]. Therefore the percuta-
neous approach is favoured. In more heavily morbid patients,
ablation under moderate sedation may be preferable to GA.
Consensus level: strong
Test-of-time approach
The rationale for this approach is that ablation is often suc-
cessful in treating small tumours without the need for resec-
tion but should ablation be unsuccessful, resection is still fea-
sible. At the same time an interval is built into the patients’
treatment programme so that as undetectable microscopic liv-
er metastases enlarge, they become detectable on imaging.
This apparent disease progression often changes the patient’s
status from resectable to unresectable. This test of time ap-
proach was first described in 2003 [63]. In that paper, of the
88 patients treated, 26 % remained tumour-free, negating the
need for resection, 50 % developed more widespread disease
progression and became unsuitable for resection, and 24 %
underwent resection. A modified test-of-time approach has
been used by another group for poor risk patients, i.e. those
who had positive margins at liver resection or those recurring
within 6 months of liver resection [35]. The test-of-time ap-
proach was considered an acceptable application.
Consensus level: moderate
Patient choice
This indication applies to a small percentage of all patients
undergoing RF ablation (2–19 %) [36, 37] who opt for abla-
tion despite being suitable for resection. RF ablation can be
undertaken with the proviso that patients should have had an
opportunity to discuss the probable outcomes with each of the
relevant specialties and in this way make a well informed
decision.
Consensus level: strong
What is the optimal timing of chemotherapy
for patients receiving combined treatment?
Neoadjuvant chemotherapy
Neoadjuvant chemotherapy is advocated in patients who are
not suitable for ablation de novo, in the hope that downsizing
will permit definitive treatment with resection or ablation. A
5-year survival of 34 % has been reported by one group using
RF ablation in a small group of 36 patients following neoad-
juvant chemotherapy [73]. A technical limitation to treating
patients who have undergone neoadjuvant chemotherapy pri-
or to ablation can be difficulty in visualising treated hepatic
tumours for example because of the development of
hepatosteatosis±tumour shrinkage. Additional techniques to
define the tumours in the presence of chemotherapy-induced
hepatosteatosis and tumour shrinkage,for example MRI with
liver specific contrast agents, and larger treatment margins are
recommended. Attempts to target and ablate tumours that are
no longer visible on imaging using historical data and fusion
techniques may be unsuccessful. However, tumours that have
Bdisappeared’ on imaging are still detectable in pathology
specimens and as they enlarge are very likely to ‘re-appear’
on follow-up imaging, so there should be a plan in place to
treat these tumours when they do re-declare [74, 75].
Adjuvant chemotherapy
There is some evidence that adjuvant chemotherapy after liver
resection maybe beneficial. A retrospective study in 235 pa-
tients showed a 5-year survival of 53 % in a subgroup of 99
patients who received (mostly 5FU-leucovorin based) adju-
vant chemotherapy versus 25 % in those who did not have
post-operative chemotherapy [76]. Two randomised studies,
also using 5FU-leucovorin chemotherapy, showed a non-
significant trend towards a benefit (p=0.125 and 0.13, respec-
tively). When these studies were pooled the median relapse-
free survival in the chemotherapy arm was 28 months versus
19 in the control arm (p=0.058) and the overall survival was
62 vs. 47 months (p=0.095) [77, 78]. A randomised phase III
trial of perioperative (six cycles prior followed by six cycles
after resection) chemotherapy using FOLFOX (5FU and
Oxaliplatin) showed a 7.3 % increase in PFS at 3 years in
the chemotherapy arm (p=0.058) [79]. A recently published
follow-up report of the same cohort at 8.5 years showed no
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difference in overall survival, but this regime is still recom-
mended because of the improvement in PFS [80].
Similarly there is early data to support adjuvant chemother-
apy after ablation. Machi et al. [33] studied RF ablation as a
first-line treatment versus RF ablation following chemothera-
py and showed an increased overall survival of 26 months
(48 months for first-line RF ablation vs. 22 months for RF
ablation after chemotherapy). However, this study was insuf-
ficiently powered for statistical analysis. Siperstein et al. [81]
showed an overall survival of 28 months versus 19 months for
those who received chemotherapy after laparoscopic ablation
(p=0.02) and another paper reported a 10-year survival of
18 % in patients treated with percutaneous ablation and adju-
vant chemotherapy using 5FU and Irinotecan [36].
As percutaneous ablation carries a low morbidity, the inter-
val between ablation and adjuvant chemotherapy can be less
than after open ablation or resection, with many commencing
chemotherapy approximately 2 weeks post-ablation.
Although more evidence needs to be acquired, ablation
plus chemotherapy seems to be better than either ablation or
chemotherapy alone. This is in line with animal data. In a
series of laboratory studies, larger ablations were consistently
achieved when a combination of Doxil and ablation was used
as compared with thermal ablation alone [82, 83]. For patients
with ablatable disease at presentation, adjuvant chemotherapy
may be preferred to neoadjuvant chemotherapy. Patients who
cannot undergo chemotherapy, for example due to significant
co-morbidity, side effects or poor tolerance often tolerate ab-
lation and should be considered for ablation if the size and
location of their tumours is appropriate [7].
Consensus level: strong
Can ablation be used to debulk liver metastases followed
by chemotherapy?
Surgical debulking is an established part of the management
of some tumours, for example metastatic ovarian cancer.
There has been some discussion in the surgical community
of using resection to debulk colorectal metastases prior to
systemic chemotherapy but this is not evidence-based. As a
focal minimally invasive technique, ablation is a less effective
debulking tool. It is therefore preferable to concentrate re-
sources on performing ablation with curative intent in limited
disease.
Consensus level: strong
Choice of approach
Local recurrence
A decrease in local recurrence rates following open ablation
compared to other approaches has not been confirmed in all
studies. Local recurrence following open ablation varies
between 6 % and 60 % and following percutaneous ablation
between 10 % and 52 % (Table 3) [44, 46, 84, 85]. All
studies report lower rates of local recurrence in smaller
tumours.
Need for invasive staging
One often quoted reason for an intra-operative approach is
the need for invasive staging. There are several conflicting
papers showing both a substantial and a minimal benefit
from open or laparoscopic staging [86, 87]. In the current
era of excellent preoperative staging with good quality
CECT, MRI and PET-CT, the benefit of operative staging
is likely to be very small [86].
We further stress the percutaneous approach is the least
invasive method for performing ablation. Open ablation
carries an increased mortality and morbidity over percuta-
neous ablation [34, 41, 42] and should be reserved for
patients undergoing resection for un-ablatable disease
including:
1) Bulk disease
2) Resection of multiple clustered tumours in one area with
ablation to between one and four tumours in the remnant
liver.
Laparoscopic ablation
This technique requires a high level of expertise but has been
developed in a few centres who report a reduction in morbid-
ity, cost and hospital stay as compared with open ablation
(Table 2) [5, 30]. Tumours that are adherent to vulnerable
structures but are otherwise suitable for ablation may be best
approached laparoscopically. However, a percutaneous ap-
proach should be favoured in tumours that are treatable either
laparoscopically or percutaneously in order to minimise ex-
pense of hospital stay, morbidity and mortality [7, 30, 32, 40,
43].
Consensus level: strong
Access to Interventional Oncology ablation programmes
and expertise
An interventional oncologist qualified in percutaneous abla-
tion should be a standing member of the institutional colorec-
tal cancer liver metastasis tumour board making recommen-
dations on management. We feel that the successful selection
of patients suitable for tumour ablation is predicated on pur-
poseful involvement of a qualified interventional oncologist in
the decision making process.
Consensus level: strong
3450 Eur Radiol (2015) 25:3438–3454
Future indications for thermal ablation: can thermal
ablation be used in resectable disease, in particular
in small, solitary tumours, <3 cm in diameter?
The old mantra that the only chance of cure lies with resection
is no longer true. Thermal ablation can and does result in cure
in selected patients [42, 88].
Whilst there are several retrospective studies showing bet-
ter survival following resection than following ablation, the
two techniques are nearly always applied selectively with ab-
lation being used in the patient group who are expected to fare
less well [5, 85]. More often than not the ablation group has
more disease, including extra-hepatic disease, is older and has
more co-morbidities, or attempts have been made to ablate
larger, >5-cm, tumours which are unlikely to succeed. When
ablation has been applied as first-line therapy to patients with
resectable disease, the 5-year survival results have been very
similar to surgical series [30, 61].
Although there is one study showing comparable local tu-
mour progression between wedge resection, anatomical resec-
tion and ablation [45], most surgical series report higher local
tumour progression following ablation than after resection
[43]. Despite this the overall survival is often similar [34].
There are five retrospective studies that show comparable
survival between resection and ablation particularly when ab-
lation is applied to smaller, <3-cm tumours. The results from
Kim, Otto and Reuter have already been discussed [32, 34,
61]. Two other, smaller series also showed comparable results.
Hur [89] reported on 23 patients who underwent resection
compared with 15 who underwent either percutaneous or in-
traoperative RF ablation for </=3-cm tumours. The 5-year
survival was 56 % and 55 %, respectively. Oshowo [90] com-
pared resection and percutaneous ablation in solitary tumours
of any size and found a similar 3-year survival. All of these
studies are relatively small; more evidence is required. The
possibility of a prospective RCT between surgical resection
and ablation has been debated for over a decade and would be
welcomed by this panel of experts. Likewise wewould call for
direct comparison to other therapies, for example chemo/
radioembolisation or focal radiation therapy.
Consensus level: strong
Future directions
The gold standard RCT data, is very difficult to achieve and
expensive. Vested interests, evolving technologies and pa-
tient resistance to randomisation are substantial barriers.
The only attempted randomised trial of chemotherapy±
ablation (EORTC 40004) failed to accrue and the authors
concluded that the chances of a further RCTwere minimal.
In addition changes in chemotherapy over the time-course
of the study and significant differences in salvage therapy
meant the initial endpoints and statistical framework
proved inadequate.
In the interim, more, clearer and cleaner published data are
required. Papers dealing with one tumour type, for example
colorectal or breast liver metastases rather than mixed tumour
populations, uniform technologies and approaches, larger se-
ries, more patient details and more specific patient groups are
required to clarify what ablation can offer, and local recur-
rence rates should be reduced. Patients need better access to
ablation programmes and to interventional oncology
expertise.
Conclusion
Thermal ablation is widely, but not universally, accepted as
part of the management of patients with unresectable colorec-
tal liver metastases. Not all patients who are suitable for abla-
tion have access to good quality ablation expertise. Further-
more, ablation has not yet reached its full potential; more can
be done. It is our intention that these recommendations will
facilitate the judicious selection of the patients who are most
likely to benefit from ablation therapy and provide a unified
interventional oncology perspective as we attempt to generate
greater consensus from other oncology disciplines for the use
of this clearly beneficial technology.
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